Antimicrobial resistance in European isolates of Pseudomonas aeruginosa

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 19, Issue 5, 2000, Pages 370-374

  Fluit, A C ^a   Verhoef, J ^a   Schmitz, F J ^a   Mittermayer, H ^b   Struelens, M ^b   Goldstein, F ^b   Jarlier, V ^b   Etienne, J ^b   Courcol, P R ^b   Daschner, F ^b   Hadding, U ^b   Legakis, N ^b   Schito, G C ^b   Raponi, G ^b   Heczko, P ^b   Hyrniewicz, W ^b   Costa, D ^b   Perea, E ^b   Baquero, F ^b   Martin Alvarez, R ^b   Bille, J ^b   French, G ^b   Andoni, R ^b   Korten, V ^b   Unal, S ^b   Gur D ^b   Keller, N ^b   more..

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; ANTIINFECTIVE AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; CEFEPIME; CEFTRIAXONE; CIPROFLOXACIN; GENTAMICIN; IMIPENEM; MEROPENEM; PIPERACILLIN; TAZOBACTAM; TICARCILLIN; TIMENTIN; TOBRAMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; GEOGRAPHIC DISTRIBUTION; GRAM NEGATIVE INFECTION; HOSPITAL INFECTION; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA;

EID: 0034125919     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/s100960050497     Document Type: Article

References (14)

1. 1. Edgeworth JD, Treacher DF, Eykyn SJ: A 25-year study of nosocomial bacteremia in adult intensive care unit. Critical Care Medicine (1999) 27:1421-1428
2. 2. Cristino JM: Correlation between consumption of antimicrobials in humans and development of resistance in bacteria. International Journal of Antimicrobial Agents (1999) 12:199-202
3. 3. Pitt TL, Barth AL: Pseudomonas aeruginosa and other medically important pseudomonads. In: Emerson AM, Hawkey PM, Gillespie SH (eds): Principles and practice of clinical bacteriology. Wiley and Sons, Chichester (1997) pp 494-517
4. 4. Bergogne-Bérézin E: Pseudomonads and miscellaneous gram-negative bacilli: In: Armstrong D, Cohen J (eds): Infectious Diseases (1999) pp 8.18.1-8.18.22
5. 5. National Committee for Clinical Laboratory Standards: Performance standards for antimicrobial susceptibility testing. Supplement Tables. NCCLS, Wayne, PA (1998)
6. 6. Pflaller MA, Jones RN, Doern GV, Kugler K, and the SENTRY Participants Group: Bacterial pathogens isolated from patients with blood stream infections: frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997). Antimicrobial Agents and Chemotherapy (1998) 42:1762-1770
7. 7. Doern GV, Jones RN, Pfaller MA, Kugler KC, Beach ML: Bacterial pathogens isolated from patients with skin and soft tissue infections: frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997). SENTRY Study Group (North America). Diagnostic Microbiology and Infectious Diseases (1999) 34:65-72
8. 8. Diekema DJ, Pfaller MA, Jones RN, Doern GV, Winokur PL, Gales AC, Sader HS, Kugler K, Beach M, and the SENTRY Participants Group (Americas): Survey of blood-stream infections due to gram-negative bacilli: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, and Latin America for the SENTRY Animicrobial Surveillance Program, 1997. Clinical Infectious Diseases (1999) 29:595-607
9. 9. Sader HS, Jones RN, Gales AC, Winokur P, Kugler KC, Pfaller MA, Doern GV, and the SENTRY Latin America Study Group: Antimicrobial susceptibility patterns for pathogens isolated from patients in Latin American medical centers with a diagnosis of pneumonia: Analysis of results from the SENTRY Antimicrobial Surveillance Program (1997). Diagnostic Microbiology and Infectious Diseases (1999) 32:289-301
10. 10. Yamaguchi K, Mathai D, Biedenbach DJ, Lewis MT, Gales AC, Jones RN: Evaluation of the in vitro activity of six broad-spectrum beta-lactam antimicrobial agents tested against over 2,000 clinical isolates from 22 medical centers in Japan. Japan Antimicrobial Resistance Study Group. Diagnostic Microbiology and Infectious Diseases (1999) 34:123-134
11. 11. Ben-Mahrez K, Rejiba S, Belhadj C, Belhadj O: Beta-lactamase-mediated resistance to extended spectrum cephalosporins among clinical isolates of Pseudomonas aeruginosa. Research in Microbiology (1999) 150:403-406
12. 12. Danel F, Hall LM, Gür D, Livermore DM: OXA-16, a further extended-spectrum variant of OXA-10 beta-lactamse, from two Pseudomonas aeruginosa isolates. Antimicrobial Agents and Chemotherapy (1998) 42:3117-3122
13. 13. Germ M, Yoshihara E, Yoneyama H, Nakae T: Interplay between the efflux pump and the outer membrane permeability barrier in fluorescent dye accumulation in Pseudomonas aeruginosa. Biochemical Biophysical Research Communications (1999) 261:452-455
14. 14. Lomovskaya O, Lee A, Hoshino K, Ishida H, Mistry A, Warren MS, Boyer E, Chamberland S, Lee VJ: Use of a genetic approach to evaluate the consequences of inhibition of efflux pumps in Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy (1999) 43:1340-1346